Navigation Links
ThromboGenics N.V. - Business Update
Date:5/13/2008

half year results on the 28th August, 2008.

About ThromboGenics

ThromboGenics is a biotechnology company focused on discovery and development of biopharmaceuticals for the treatment of a range of vascular diseases. The Company has several programs in Phase II clinical development including microplasmin, which is being evaluated as a treatment for vitreoretinal disorders and as a thrombolytic agent for vascular occlusive diseases such as acute stroke. ThromboGenics is also developing novel antibody therapeutics in collaboration with BioInvent International; these include TB-402 (Anti-Factor VIII), scheduled to enter Phase II clinical development in late 2008, and TB-403 (Anti-PlGF), which has begun Phase I clinical trials for the treatment of cancer. ThromboGenics has built strong links with the University of Leuven and has exclusive rights to certain therapeutics developed at the University. ThromboGenics is headquartered in Leuven, Belgium and has subsidiaries in Dublin, Ireland and New York, U.S. The Company is listed on Eurolist by Euronext Brussels under the symbol THR. More information is available at http://www.thrombogenics.com.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the prospect
'/>"/>

SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related biology technology :

1. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
2. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
3. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
4. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
5. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
6. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
7. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
8. ThromboGenics Announces 2007 Full Year Results
9. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
10. Boston Scientific to Explore Sale of Cardiac Surgery and Vascular Surgery Businesses
11. DuPont Leaders Brief Investors on Agriculture Businesses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/10/2009)... Endologix, Inc. (Nasdaq: ELGX ), developer of ... that Dan Lemaitre, former President and CEO of ... effective December 11, 2009. Endologix now has ... Franklin D. Brown, Chairman of the Board, said, ... the Endologix Board of Directors. He has ...
(Date:12/10/2009)... - YM BioSciences Inc. (NYSE Amex: YMI ... company that identifies and advances a diverse portfolio ... development, today provided an update on the proposed ... Cytopia Ltd. into YM, details of which were ... directors of Cytopia has unanimously recommended that its ...
(Date:12/10/2009)... Pharmaceuticals, Inc.,(OTC Bulletin Board: LTUS) ("Lotus" or ... prescription drugs and licensed national seller of ... ("PRC"), today reported that,effective December 1, 2009, ... Lotus,appointed Mr. Jinzhong HAN to be General ... Division"). , Mr. ...
(Date:12/10/2009)... Antibodies Produces First Candidates Which Selectively Target ... Dec. 10 /PRNewswire-FirstCall/ - YM BioSciences Inc. ... results of a collaborative program between YM ... of Canada,s Biotechnology Research Institute (NRC-BRI). Utilizing ... to generate novel antibodies that target cell ...
Breaking Biology Technology:Endologix Appoints Dan Lemaitre to its Board of Directors 2YM BIOSCIENCES OFFER FOR CYTOPIA APPROVED TO PROCEED TO SHAREHOLDER VOTE BY AUSTRALIAN COURT 2YM BIOSCIENCES OFFER FOR CYTOPIA APPROVED TO PROCEED TO SHAREHOLDER VOTE BY AUSTRALIAN COURT 3YM BIOSCIENCES OFFER FOR CYTOPIA APPROVED TO PROCEED TO SHAREHOLDER VOTE BY AUSTRALIAN COURT 4Lotus Pharmaceuticals, Inc. Appoints OTC Division Head 2Lotus Pharmaceuticals, Inc. Appoints OTC Division Head 3YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 2YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 3YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 4YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 5
... , , ... , , , ... advances in microfabrication,technology, the development,of a fully automated laboratory on ... handling and,biochemical analysis, "lab-on-a-chip",is revolutionizing life science research. , ...
... , ... , , This Application Note describes ... be used to determine the efficiency,of transfection of mammalian cells using ... with,expression vectors encoding GFP from two different sources, and optimization,of transfection ...
... , , ... , , , ... become an essential tool in any,laboratory working on cell-based studies. ... also the determination of growth factor,and cytokine activity. Even more ...
Other Biology Technology:Agilent 2100 Bioanalyzer,Automated Analysis System 2Agilent 2100 Bioanalyzer,Automated Analysis System 3Agilent 2100 Bioanalyzer,Automated Analysis System 4Agilent 2100 Bioanalyzer,Automated Analysis System 5Agilent 2100 Bioanalyzer,Automated Analysis System 6Monitoring transfection efficiency by,green fluorescent protein (GFP) detection,with the Agilent 2100 bioanalyzer 2Monitoring transfection efficiency by,green fluorescent protein (GFP) detection,with the Agilent 2100 bioanalyzer 3Monitoring transfection efficiency by,green fluorescent protein (GFP) detection,with the Agilent 2100 bioanalyzer 4Monitoring transfection efficiency by,green fluorescent protein (GFP) detection,with the Agilent 2100 bioanalyzer 5Monitoring transfection efficiency by,green fluorescent protein (GFP) detection,with the Agilent 2100 bioanalyzer 6Monitoring transfection efficiency by,green fluorescent protein (GFP) detection,with the Agilent 2100 bioanalyzer 7Cell Proliferation and Viability Measurement 2Cell Proliferation and Viability Measurement 3Cell Proliferation and Viability Measurement 4
(Date:12/14/2009)... The most comprehensive study to date of the proteins ... may provide important clues to how similar regeneration could ... School of Science at Indiana University-Purdue University Indianapolis and ... limbs of axolotls, a type of salamander that has ... level of amputation, with the hope that this knowledge ...
(Date:12/14/2009)... team of researchers from the Astrobiology Centre (INTA-CSIC) has ... essential to the formation of the most basic biological ... In order to carry out this study, published in ... recreated the chemical conditions of the early Earth. , ... in ammoniac solutions it produces hydrogen cyanide, a substance ...
(Date:12/14/2009)... of the United Nations Framework Convention on Climate ... Agency hosted the ,Bend the Trend, event on ... platform and premiere the screening of the new ... of Europe, a joint project of the European ... and ESA, is a series of short films ...
Breaking Biology News(10 mins):IUPUI researchers tackle protein mechanisms behind limb regeneration 2Prussian blue linked to the origin of life 2'Environmental Atlas of Europe' unveiled at COP15 2Microlife WatchBP Series is Proud to Present its Total Concept at the World Hypertension Congress 5866 1Microlife WatchBP Series is Proud to Present its Total Concept at the World Hypertension Congress 5866 2Microlife WatchBP Series is Proud to Present its Total Concept at the World Hypertension Congress 5866 3Siemens Unveils New Hearing Loss Options at SPLASH 3A ADAs 2009 Convention 5863 1Siemens Unveils New Hearing Loss Options at SPLASH 3A ADAs 2009 Convention 5863 2Siemens Unveils New Hearing Loss Options at SPLASH 3A ADAs 2009 Convention 5863 3Siemens Unveils New Hearing Loss Options at SPLASH 3A ADAs 2009 Convention 5863 4Screening for Cardiovascular Diseases Difficult but Necessary 60379 1Screening for Cardiovascular Diseases Difficult but Necessary 60379 2
... Davis, today launched a new "One,Health" program to conserve ... only the gorillas but also the people and,the other ... central,Africa. , With $750,000 in funding from the David ... Gorilla One Health,Program in the School of Veterinary Medicine,s ...
... are astonished at the spectacular recovery of certain coral reefs ... coral bleaching event in 2006. , That year high sea ... Islands, in the southern part of the GBR. The ... seaweed an event that can spell the total loss ...
... A discovery made by researchers at Wake Forest ... explain how some people without a genetic predisposition to ... published this month in the Journal of Neuroscience ... of neurobiology and anatomy, and colleagues, report discovering that ...
Other Biology News:UC Davis launches 'One Health' care for wild mountain gorillas and human neighbors 2UC Davis launches 'One Health' care for wild mountain gorillas and human neighbors 3UC Davis launches 'One Health' care for wild mountain gorillas and human neighbors 4UC Davis launches 'One Health' care for wild mountain gorillas and human neighbors 5Reef boom beats doom 2Researchers discover that gene switches on during development of epilepsy 2Researchers discover that gene switches on during development of epilepsy 3
... This reagent has been developed ... for the reduction of nonspecific background ... Traditional methods describe blocking peroxidase with ... hydrogen peroxide in combination with additional ...
Phospho-Btk (Tyr223) Antibody...
Rad51B...
p27 rabbit polyclonal antibody...
Biology Products: